OR WAIT 15 SECS
Aragen Bioscience has licensed ProteoNic Biotechnology’s 2G UNic recombinant protein production technology, which increases manufacturing efficiency and reduces cost of goods for recombinant biologicals.
Aragen Bioscience has entered into an agreement with ProteoNic Biotechnology for the commercial use of ProteoNic’s 2G UNic recombinant protein production technology, the companies announced Sept. 9, 2015. Under the terms of the agreement, Aragen gains the rights to apply this technology to the development of recombinant cell lines. The technology enhances commercial production levels compared with current methods, according to the company, which in turn increases manufacturing efficiency and reduces cost of goods for recombinant biologicals.
ProteoNic’s proprietary, second-generation mammalian expression technology is based on the synergistic effect of novel genetic elements, which exert a positive effect on recombinant protein-production levels as well as on stability of expression. The technology has been demonstrated to be broadly applicable to various protein targets, multiple host-cell lines, and selection systems. It can be combined with most other production technologies for increased effectiveness.
“We have performed evaluations of ProteoNic’s 2G UNic technology for a number of products in stable and transient protein expression settings,”commented Oren Beske, COO at Aragen Bioscience, in a press release. “To date, we have consistently obtained a significant increase in cell culture productivity. We believe that the combination of this technology and Aragen’s services will provide significant value to our current and future clients.”
Under the terms of the agreement, Aragen will offer cell-line development services including ProteoNic technology for production of biologicals for commercial use under a fee for service relationship. The ProteoNic technology is offered without a royalty.
Source: Aragen Bioscience